MARKET

DWTX

DWTX

Dogwood Therapeutics
NASDAQ
2.950
-0.220
-6.94%
After Hours: 2.950 0 0.00% 16:10 02/09 EST
OPEN
3.060
PREV CLOSE
3.170
HIGH
3.160
LOW
2.920
VOLUME
50.03K
TURNOVER
--
52 WEEK HIGH
14.69
52 WEEK LOW
2.600
MARKET CAP
94.64M
P/E (TTM)
-0.1184
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DWTX last week (0202-0206)?
Weekly Report · 23h ago
Dogwood Therapeutics: Strengthened Capital Structure, Advancing Pain Pipeline, and Extended IP Support a Buy-Rated Risk-Reward Profile
TipRanks · 5d ago
Dogwood Reaches 50% Enrollment In Ongoing Halneuron Phase 2b Trial
Benzinga · 02/02 13:39
Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial
TipRanks · 02/02 13:35
Dogwood Therapeutics Reaches 50% Enrollment in Phase 2b Halneuron Trial for Chemotherapy-Induced Neuropathic Pain
Reuters · 02/02 13:31
DOGWOOD THERAPEUTICS ANNOUNCES 50% ENROLLMENT IN ONGOING HALNEURON® PHASE 2B TRIAL, TOP LINE RESULTS ANTICIPATED IN Q3 2026
Reuters · 02/02 13:30
DOGWOOD THERAPEUTICS INC - HALT-CINP TRIAL RESULTS EXPECTED IN Q3 2026
Reuters · 02/02 13:30
Weekly Report: what happened at DWTX last week (0126-0130)?
Weekly Report · 02/02 09:24
More
About DWTX
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

Webull offers Dogwood Therapeutics Inc stock information, including NASDAQ: DWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DWTX stock methods without spending real money on the virtual paper trading platform.